What Researchers Did
Researchers at an Australian hospital validated a new outcome scoring tool (NICCE) by testing it on 235 patients with flesh-eating bacterial infections (necrotising soft tissue infections) admitted between 2012 and 2021.
What They Found
Overall survival was 91.1%. The NICCE tool successfully separated high-acuity from low-acuity patients, with only 34% of sicker patients meeting the 'success' threshold versus 65% of lower-acuity patients. Meeting NICCE criteria was associated with significantly fewer ICU days, ventilator days, and shorter hospital stays across all patient groups.
What This Means for Canadian Patients
Necrotising fasciitis (flesh-eating disease) is a serious condition seen in Canadian emergency settings. This tool helps researchers design better clinical trials for HBOT in these infections by using a more meaningful outcome than survival alone. As HBOT trials for flesh-eating disease become more rigorous, Canadian patients may eventually benefit from clearer evidence guiding its use.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This retrospective validation was done at a single Australian hospital, and the NICCE tool still needs prospective testing before it can be used to guide individual patient care.